Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Tracey Winkworth
North London & East Anglia
When multiple myeloma returns, think BCMA, think BLENREP
For Great Britain (GB) healthcare professionals only - Not available in Northern Ireland (NI)
BLENREP is only available via the private market.
BLENREP has a conditional marketing authorisation.
Get in touch with your local GSK Key Account Manager today to learn more and access useful patient resources.
Adverse event reporting information can be found at the bottom of this page.
When multiple myeloma returns, think BCMA, think BLENREP
Consider the first and only licensed B-cell maturation antigen (BCMA) targeted antibody drug conjugate treatment for 5L+ patients with triple-class refractory multiple myeloma1
Abbreviations:
BCMA, B-cell maturation antigen; GB, Great Britain; NI, Northern Ireland; 5L+, 5th line plus.
Prescribing information can be found at the top of this webpage, or here.
BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.1
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
References
- BLENREP Summary of Product Characteristics
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or email us on UKSafety@gsk.com.
January 2024 | PM-GB-BLM-WCNT-230001 (V3.0)
